WO2007089335A2 - Multicyclic amino acid derivatives and methods of their use - Google Patents
Multicyclic amino acid derivatives and methods of their use Download PDFInfo
- Publication number
- WO2007089335A2 WO2007089335A2 PCT/US2006/047579 US2006047579W WO2007089335A2 WO 2007089335 A2 WO2007089335 A2 WO 2007089335A2 US 2006047579 W US2006047579 W US 2006047579W WO 2007089335 A2 WO2007089335 A2 WO 2007089335A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- phenyl
- optionally substituted
- alkyl
- propanoic acid
- Prior art date
Links
- 0 CC(C(C(O*)=O)N*)N*(C)C(CCC1)CCCC1(C)C1(*)CCCCC(C)(**2CCCCCCCC2)CCCC1 Chemical compound CC(C(C(O*)=O)N*)N*(C)C(CCC1)CCCC1(C)C1(*)CCCCC(C)(**2CCCCCCCC2)CCCC1 0.000 description 6
- DTKDANCMEMZESZ-NRFANRHFSA-N COc(ccc(CNc1nc(-c2ccc(C[C@@H](C(O)=O)N)cc2)cnc1)c1)c1OC1CCCC1 Chemical compound COc(ccc(CNc1nc(-c2ccc(C[C@@H](C(O)=O)N)cc2)cnc1)c1)c1OC1CCCC1 DTKDANCMEMZESZ-NRFANRHFSA-N 0.000 description 1
- NOGGRGSSBDYZGI-ZHRRBRCNSA-N C[C@H](c1cc(cccc2)c2cc1)N(C)c1cc(-c2ccc(C[C@@H](C(O)=O)N)cc2)nc(N)n1 Chemical compound C[C@H](c1cc(cccc2)c2cc1)N(C)c1cc(-c2ccc(C[C@@H](C(O)=O)N)cc2)nc(N)n1 NOGGRGSSBDYZGI-ZHRRBRCNSA-N 0.000 description 1
- XWARTPRNGAEHGO-RCDNUKIMSA-N Cc1ccc(C(C(F)(F)F)Oc2cc(C3C=CC(C[C@@H](C(O)=O)N)=CC3)nc(N)n2)cc1 Chemical compound Cc1ccc(C(C(F)(F)F)Oc2cc(C3C=CC(C[C@@H](C(O)=O)N)=CC3)nc(N)n2)cc1 XWARTPRNGAEHGO-RCDNUKIMSA-N 0.000 description 1
- IDABDDFSKOAXMD-NRFANRHFSA-N N[C@@H](Cc(cc1)ccc1-c(nc1)cnc1NCc1cc2ccccc2cc1)C(O)=O Chemical compound N[C@@H](Cc(cc1)ccc1-c(nc1)cnc1NCc1cc2ccccc2cc1)C(O)=O IDABDDFSKOAXMD-NRFANRHFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/44—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES06849951T ES2395392T3 (es) | 2005-12-29 | 2006-12-12 | Derivados aminoácidos multicíclicos y métodos de su uso |
DK06849951.6T DK1984344T3 (da) | 2005-12-29 | 2006-12-12 | Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf |
EP06849951A EP1984344B1 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
BRPI0620756-1A BRPI0620756B1 (pt) | 2005-12-29 | 2006-12-12 | Derivados de aminoácido multicíclicos, formulação farmacêutica compreendendo os mesmos e seus usos para inibir a atividade de triptofano hidroxilase 1 (tph1) |
PL06849951T PL1984344T3 (pl) | 2005-12-29 | 2006-12-12 | Multicykliczne pochodne aminokwasów oraz sposób ich stosowania |
AU2006337137A AU2006337137B2 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
JP2008548561A JP5483883B2 (ja) | 2005-12-29 | 2006-12-12 | 多環式アミノ酸誘導体及びその使用方法 |
CN2006800499070A CN101351451B (zh) | 2005-12-29 | 2006-12-12 | 多环氨基酸衍生物及其使用方法 |
KR1020087015697A KR101360621B1 (ko) | 2005-12-29 | 2006-12-12 | 다환식 아미노산 유도체 및 그의 사용 방법 |
CA2635531A CA2635531C (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
EA200870127A EA019879B1 (ru) | 2005-12-29 | 2006-12-12 | Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные |
NZ568946A NZ568946A (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
IL191998A IL191998A (en) | 2005-12-29 | 2008-06-05 | Pharmaceutical compounds and compositions of multicyclic amino acid history and their use |
NO20083324A NO344848B1 (no) | 2005-12-29 | 2008-07-28 | Multisykliske aminosyrederivater og fremgangsmåter for deres anvendelse |
HK09102308.4A HK1124841A1 (en) | 2005-12-29 | 2009-03-11 | Multicyclic amino acid derivatives and methods of their use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75495505P | 2005-12-29 | 2005-12-29 | |
US60/754,955 | 2005-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007089335A2 true WO2007089335A2 (en) | 2007-08-09 |
WO2007089335A3 WO2007089335A3 (en) | 2007-10-11 |
Family
ID=38327831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/047579 WO2007089335A2 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
Country Status (21)
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1848435A2 (en) * | 2005-01-25 | 2007-10-31 | Synta Pharmaceuticals Corporation | Compounds for inflammation and immune-related uses |
WO2008073933A2 (en) | 2006-12-12 | 2008-06-19 | Lexicon Pharmaceuticals, Inc. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
WO2009002964A1 (en) * | 2007-06-26 | 2008-12-31 | Lexicon Pharmaceuticals, Inc. | Methods of treating serotonin-mediated diseases and disorders |
WO2009002970A1 (en) * | 2007-06-26 | 2008-12-31 | Lexicon Pharmaceuticals, Inc. | Compositions comprising tryptophan hydroxylase inhibitors |
WO2009014972A1 (en) * | 2007-07-26 | 2009-01-29 | Lexicon Pharmaceuticals, Inc. | Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein |
WO2009029499A1 (en) * | 2007-08-24 | 2009-03-05 | Lexicon Pharmaceuticals, Inc. | Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
WO2009042733A1 (en) * | 2007-09-28 | 2009-04-02 | Lexicon Pharmaceuticals, Inc. | Solids forms of ( s) -ethyl 2-amin0-3- (4- (2 -amino- 6- ( (r) -1- (4-chl0r0-2- o-methyl-ih-pyrazol- 1-yl) phenyl) -2, 2, 2-trifluorethoxy) -pyrimidin-4-yl) phenyl) propanoate |
WO2009048864A1 (en) * | 2007-10-08 | 2009-04-16 | Lexicon Pharmaceuticals, Inc. | Solid forms of (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
WO2010039957A1 (en) * | 2008-10-03 | 2010-04-08 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors and methods of their use |
WO2010047712A1 (en) * | 2008-10-24 | 2010-04-29 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
WO2010062829A1 (en) * | 2008-11-28 | 2010-06-03 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for treating osteoporosis |
WO2010065333A1 (en) * | 2008-12-01 | 2010-06-10 | Lexicon Pharmaceuticals, Inc. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis |
EP2282756A1 (en) * | 2008-03-31 | 2011-02-16 | The Trustees of Columbia University in the City of New York | Methods of diagnosing, preventing and treating bone mass diseases |
JP2011511008A (ja) * | 2008-02-04 | 2011-04-07 | マーキュリー セラピューティクス,インコーポレイテッド | Ampk調節因子 |
WO2011056916A1 (en) * | 2009-11-05 | 2011-05-12 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of cancer |
US20130053343A1 (en) * | 2009-11-02 | 2013-02-28 | The Trustees of Columbia University in th City of | Compounds and methods for inhibiting serotonin synthesis |
WO2013131872A1 (en) * | 2012-03-05 | 2013-09-12 | Ge Healthcare Limited | Imaging neural activity |
WO2014195847A2 (en) | 2013-06-03 | 2014-12-11 | Actelion Pharmaceuticals Ltd | Novel use of stable isotope labeled l-tryptophan |
WO2015075023A1 (en) | 2013-11-19 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
WO2015075025A1 (en) | 2013-11-19 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase |
WO2015089137A1 (en) * | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
JP2015164925A (ja) * | 2006-11-15 | 2015-09-17 | ワイエム・バイオサイエンスィーズ・オーストラリア・ピーティーワイ・リミテッドYM Biosciences Australia Pty Ltd | キナーゼ活性の阻害剤 |
US9199994B2 (en) | 2013-09-06 | 2015-12-01 | Karos Pharmaceuticals, Inc. | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
WO2016177690A1 (en) | 2015-05-04 | 2016-11-10 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
US9783522B2 (en) | 2014-04-24 | 2017-10-10 | Mitsubishi Tanabe Pharma Corporation | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof |
US10894787B2 (en) | 2010-09-22 | 2021-01-19 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
US11884626B2 (en) | 2015-06-22 | 2024-01-30 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1599468T3 (da) | 2003-01-14 | 2008-02-04 | Arena Pharm Inc | 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
EP2287166A3 (en) | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
US7897763B2 (en) * | 2005-12-29 | 2011-03-01 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
US7855291B2 (en) * | 2005-12-29 | 2010-12-21 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
BRPI0620756B1 (pt) * | 2005-12-29 | 2021-06-01 | Tersera Therapeutics Llc | Derivados de aminoácido multicíclicos, formulação farmacêutica compreendendo os mesmos e seus usos para inibir a atividade de triptofano hidroxilase 1 (tph1) |
GB0705400D0 (en) * | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
CA2693400A1 (en) | 2007-07-11 | 2009-01-15 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
US20100260772A1 (en) * | 2007-09-28 | 2010-10-14 | The Trustees Of Columbia University In The City Of New York | Methods for treating or preventing diseases associated with low bone mass |
WO2010011864A2 (en) * | 2008-07-23 | 2010-01-28 | The Scripps Research Institute | Alpha-helix mimetic with functionalized pyridazine |
GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
GB0817208D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
EP2501684A2 (en) | 2009-11-19 | 2012-09-26 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
CN102711757A (zh) * | 2009-11-23 | 2012-10-03 | 莱西肯医药有限公司 | 用于治疗肠易激综合征的方法和分析法 |
US20120077831A1 (en) * | 2009-11-23 | 2012-03-29 | Philip Manton Brown | Methods and assays for the treatment of irritable bowel syndrome |
CN102753168A (zh) | 2010-02-10 | 2012-10-24 | 莱西肯医药有限公司 | 用于治疗转移性骨病的色氨酸羟化酶抑制剂 |
TWI513694B (zh) | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
JP2013530180A (ja) | 2010-06-16 | 2013-07-25 | パーデュー、ファーマ、リミテッド、パートナーシップ | アリール置換インドールおよびその使用 |
TW201245183A (en) * | 2010-11-05 | 2012-11-16 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid |
US20130303763A1 (en) | 2012-03-30 | 2013-11-14 | Michael D. Gershon | Methods and compositions for the treatment of necrotizing enterocolitis |
GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
US10308648B2 (en) | 2014-10-16 | 2019-06-04 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
EP3262028B1 (en) | 2014-12-17 | 2021-10-27 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
WO2016109501A1 (en) * | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
JP2016204314A (ja) * | 2015-04-23 | 2016-12-08 | 国立研究開発法人理化学研究所 | 化合物及び4−ボロノフェニルアラニン誘導体の製造方法 |
US11407763B2 (en) | 2017-08-24 | 2022-08-09 | Gwangju Institute Of Science And Technolgy | Tryptophan hydroxylase inhibitor and pharmaceutical composition including same |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH471146A (de) | 1966-03-16 | 1969-04-15 | Geigy Ag J R | Verfahren zur Herstellung von neuen Morpholinderivaten |
US4866181A (en) * | 1986-08-29 | 1989-09-12 | Aldrich-Boranes, Inc. | Process for producing optically active alcohols |
US4916074A (en) * | 1986-10-30 | 1990-04-10 | Chisso Corporation | Process for producing optically active compounds |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
EP0504541B1 (en) * | 1991-03-21 | 1998-07-22 | Solutia Europe N.V./S.A. | Improved catalytic process for selective alkylation of aromatic hydrocarbons |
DE4131924A1 (de) * | 1991-09-25 | 1993-07-08 | Hoechst Ag | Substituierte 4-alkoxypyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
HUT74690A (en) | 1993-11-24 | 1997-01-28 | Du Pont Merck Pharma | Novel isoxazoline and isoxazole fibrinogen receptor antagonists process for producing them and pharmaceutical compositions containing them |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5543133A (en) | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
GB9518553D0 (en) | 1995-09-11 | 1995-11-08 | Fujisawa Pharmaceutical Co | New urea derivatives processes for the preparation thereof and pharmaceutical composition comprising the same |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
EP0796855B1 (de) | 1996-03-20 | 2002-02-06 | Hoechst Aktiengesellschaft | Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
US5958957A (en) * | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
US7378506B2 (en) | 1997-07-21 | 2008-05-27 | Ohio University | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
US6610502B1 (en) | 1997-08-20 | 2003-08-26 | Kyowa Medex Co., Ltd. | Compound 2-amino-3-[2-(α-mannopyranosyl)indol-3-yl]propionic acid, process for preparing the same, and method for inspecting function of living body with the novel compound |
US6455550B1 (en) | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
US6229011B1 (en) * | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
MY153569A (en) * | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
US6114326A (en) * | 1998-03-27 | 2000-09-05 | Pharmacia & Upjohn Company | Use of cabergoline in the treatment of restless legs syndrome |
US6423727B1 (en) * | 1998-04-23 | 2002-07-23 | Novartis Ag | Certain thiol inhibitors of endothelin-converting enzyme |
WO2000019994A1 (en) | 1998-10-02 | 2000-04-13 | Board Of Trustees Of The University Of Illinois | Estrogen receptor ligands |
JP2000204085A (ja) | 1998-11-13 | 2000-07-25 | Nippon Bayer Agrochem Co Ltd | イソチアゾ―ルカルボン酸誘導体および病害防除剤 |
US6677360B2 (en) | 1998-12-16 | 2004-01-13 | Bayer Aktiengesellschaft | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
EE200100317A (et) | 1998-12-16 | 2002-08-15 | Bayer Aktiengesellschaft | Uued bifenüül- ja bifenüülanaloogsed ühendid kui integriini antagonistid |
WO2001054486A1 (en) | 2000-01-26 | 2001-08-02 | Kansas State University Research Foundation | Preparation and use of polymers crosslinked with tyrosine-containing peptides |
RU2245874C2 (ru) | 1999-02-18 | 2005-02-10 | Ф.Хоффман-Ля Рош Аг | Производные тиоамида и фармацевтическая композиция |
CA2368049A1 (en) | 1999-04-13 | 2000-10-19 | Basf Aktiengesellschaft | Integrin receptor ligands |
US7045532B2 (en) * | 1999-04-30 | 2006-05-16 | Millennium Pharmaceuticals, Inc. | ACE-2 modulating compounds and methods of use thereof |
JP4156807B2 (ja) | 1999-06-01 | 2008-09-24 | エラン ファーマ インターナショナル,リミティド | 小型ミル及びその方法 |
EP1065208A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Substituted purine derivatives as inhibitors of cell adhesion |
JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
AU6903200A (en) | 1999-08-16 | 2001-03-13 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
EP1214292B1 (en) * | 1999-09-24 | 2007-06-13 | Genentech, Inc. | Tyrosine derivatives |
JP2003511355A (ja) * | 1999-10-06 | 2003-03-25 | ビーエーエスエフ アクチェンゲゼルシャフト | 併用療法のためのエンドセリンシグナル伝達経路のインヒビターおよびαvβ3受容体アンタゴニスト |
DE10028575A1 (de) | 2000-06-14 | 2002-03-14 | Basf Ag | Integrinliganden |
JP2003512423A (ja) * | 1999-10-27 | 2003-04-02 | スノル・モレキュラー・コーポレーション | 組織因子アンタゴニスト及びその使用方法 |
DE60033684T2 (de) | 1999-11-18 | 2007-12-06 | Ajinomoto Co., Inc. | Phenylalaninderivate |
US6388084B1 (en) * | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
CA2396087A1 (en) * | 1999-12-28 | 2001-07-19 | Louis Stanley Chupak | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
FR2804427B1 (fr) * | 2000-01-27 | 2002-09-06 | Rhodia Chimie Sa | Procede de preparation de cetones alpha-halogenees |
WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
DK1296705T3 (da) * | 2000-06-28 | 2012-09-17 | Prana Biotechnology Ltd | Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom |
US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US7015216B2 (en) * | 2000-07-21 | 2006-03-21 | Elan Pharmaceuticals, Inc. | Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors |
AU2001278986A1 (en) * | 2000-07-21 | 2002-02-05 | Elan Pharmaceuticals, Inc. | 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors |
EP1288205B1 (en) | 2000-08-18 | 2011-02-02 | Ajinomoto Co., Inc. | Novel phenylalanine derivatives |
DE10042655A1 (de) | 2000-08-31 | 2002-03-14 | Aventis Pharma Gmbh | Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion |
MY129000A (en) * | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
AU2001290303A1 (en) | 2000-09-29 | 2002-04-15 | Ajinomoto Co., Inc. | Novel phenylalanine derivatives |
DE10112768A1 (de) * | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | Phenylderivate 3 |
TWI258469B (en) * | 2001-03-19 | 2006-07-21 | Dainippon Pharmaceutical Co | Aryl-substituted alicyclic compounds and pharmaceutical composition containing the same |
US7081460B2 (en) * | 2001-04-09 | 2006-07-25 | Ortho-Mcneil Pharmaceutical, Inc. | Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
DE60225064T2 (de) * | 2001-05-29 | 2009-01-29 | Lexicon Pharmaceuticals, Inc., The Woodlands | Neue menschliche hydroxylasen und diese codierende polynukleotide |
US6976647B2 (en) | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
CA2449490C (en) | 2001-06-05 | 2010-10-05 | Elan Pharma International Limited | System and method for milling materials |
US6951840B2 (en) * | 2001-08-31 | 2005-10-04 | Eli Lilly And Company | Lipoglycopeptide antibiotics |
JP4452899B2 (ja) * | 2001-12-13 | 2010-04-21 | 味の素株式会社 | 新規フェニルアラニン誘導体 |
US20030171368A1 (en) * | 2002-02-06 | 2003-09-11 | Werner Seitz | Pyrimidinonesulfamoylureas` |
AU2003211560A1 (en) | 2002-02-20 | 2003-09-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
CN1646508A (zh) * | 2002-04-03 | 2005-07-27 | 诺瓦提斯公司 | 作为ptp酶1b抑制剂的5-取代的1,1-二氧代-1,2,5-噻二唑烷-3-酮衍生物 |
JPWO2003089410A1 (ja) | 2002-04-19 | 2005-08-25 | 協和醗酵工業株式会社 | フェニルアラニン誘導体 |
TW200407310A (en) | 2002-06-07 | 2004-05-16 | Glaxo Group Ltd | Compounds |
GB0213122D0 (en) | 2002-06-07 | 2002-07-17 | Glaxo Group Ltd | Compounds |
DE10226921A1 (de) | 2002-06-17 | 2003-12-24 | Bayer Ag | Antibakterielle Amid-Makrozyklen |
DE10234422A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Antibakterielle Ester-Makrozyklen |
AU2003265398A1 (en) * | 2002-08-09 | 2004-02-25 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
US20050260126A1 (en) * | 2002-08-30 | 2005-11-24 | Yukitsuka Kudo | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
DE60334924D1 (de) | 2002-09-11 | 2010-12-23 | Elan Pharma Int Ltd | Anoteilchengrösse |
AU2003301903A1 (en) | 2002-11-06 | 2004-06-03 | Bristol-Myers Squibb Company | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
BR0314898A (pt) | 2002-11-19 | 2005-08-02 | Galderma Res & Dev | Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica |
JP2006514043A (ja) * | 2002-12-20 | 2006-04-27 | ファルマシア・コーポレーション | マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−2を阻害する化合物 |
ITMI20022738A1 (it) | 2002-12-23 | 2004-06-24 | Zambon Spa | Derivati ftalazinici inibitori della fosfodiesterasi 4. |
ATE412657T1 (de) | 2002-12-24 | 2008-11-15 | Astrazeneca Ab | Therapeutische quinazolin-derivate |
JPWO2004080943A1 (ja) * | 2003-03-11 | 2006-06-08 | 小野薬品工業株式会社 | シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤 |
US20050234066A1 (en) * | 2004-04-15 | 2005-10-20 | Agouron Pharmaceuticals, Inc. | Alpha substituted carboxylic acids |
US20050187266A1 (en) * | 2003-04-15 | 2005-08-25 | Pfizer Inc | Alpha substituted carboxylic acids |
US20060128956A1 (en) * | 2003-04-21 | 2006-06-15 | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky | (Purin-6-yl) amino acid and production method thereof |
AU2004247013B2 (en) * | 2003-05-14 | 2010-07-08 | Neurogenetic Pharmaceuticals, Inc. | Compounds and uses thereof in modulating amyloid beta |
BRPI0411674A (pt) * | 2003-06-20 | 2006-08-29 | Galderma Res & Dev | compostos, composição cosmética, uso cosmético de uma composição, uso de um composto, composição farmacêutica, e processo cosmético para o embelezamento da pele |
US20050042177A1 (en) | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
CA2531796A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
WO2005014534A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
JP2008502583A (ja) * | 2003-10-01 | 2008-01-31 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 抗細菌性アミド大員環 |
WO2005035551A2 (en) * | 2003-10-08 | 2005-04-21 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
MXPA06004642A (es) * | 2003-11-05 | 2006-06-27 | Hoffmann La Roche | Derivados de heteroaril como activadores de los receptores activados de proliferadores de peroxisoma (ppar). |
DE10358824A1 (de) | 2003-12-16 | 2005-07-21 | Bayer Healthcare Ag | Antibakterielle Makrozyklen mit substituiertem Biphenyl |
RU2390520C2 (ru) * | 2003-12-22 | 2010-05-27 | Адзиномото Ко., Инк. | Новые производные фенилаланина |
US20060148680A1 (en) * | 2004-01-14 | 2006-07-06 | Kieliszewski Marcia J | Glycoproteins produced in plants and methods of their use |
JP2007126358A (ja) | 2004-01-20 | 2007-05-24 | Fujiyakuhin Co Ltd | フェニルアラニン誘導体 |
EP2561884B1 (en) | 2004-02-05 | 2017-01-04 | The Ohio State University Research Foundation | Chimeric VEGF peptides |
US20050192279A1 (en) * | 2004-02-10 | 2005-09-01 | Kent Barbay | Pyridazinones as antagonists of alpha4 integrins |
US7517908B2 (en) * | 2004-05-21 | 2009-04-14 | Duke University | Method for augmenting the effects of serotonin reuptake inhibitors |
EP1778214A4 (en) * | 2004-07-27 | 2010-04-14 | Glaxosmithkline Llc | NEW BIPHENYL COMPOUNDS AND THEIR USE |
WO2006021886A1 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
BRPI0620756B1 (pt) * | 2005-12-29 | 2021-06-01 | Tersera Therapeutics Llc | Derivados de aminoácido multicíclicos, formulação farmacêutica compreendendo os mesmos e seus usos para inibir a atividade de triptofano hidroxilase 1 (tph1) |
US7897763B2 (en) * | 2005-12-29 | 2011-03-01 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
UA99270C2 (en) * | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
MX2009013982A (es) * | 2007-06-26 | 2010-04-09 | Lexicon Pharmaceuticals Inc | Composiciones que comprenden inhibidores de triptofano hidroxilasa. |
CA2693400A1 (en) * | 2007-07-11 | 2009-01-15 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
TWI439457B (zh) * | 2007-09-28 | 2014-06-01 | Lexicon Pharmaceuticals Inc | (s)-2-胺基-3-(4-(2-胺基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧)-嘧啶-4-基)苯基)丙酸乙酯之固體形式與其使用方法 |
TW200932729A (en) * | 2007-10-08 | 2009-08-01 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
-
2006
- 2006-12-12 BR BRPI0620756-1A patent/BRPI0620756B1/pt active IP Right Grant
- 2006-12-12 CA CA2635531A patent/CA2635531C/en not_active Expired - Fee Related
- 2006-12-12 WO PCT/US2006/047579 patent/WO2007089335A2/en active Application Filing
- 2006-12-12 KR KR1020087015697A patent/KR101360621B1/ko active IP Right Grant
- 2006-12-12 ZA ZA200805192A patent/ZA200805192B/xx unknown
- 2006-12-12 EA EA200870127A patent/EA019879B1/ru not_active IP Right Cessation
- 2006-12-12 US US11/638,677 patent/US7723345B2/en active Active
- 2006-12-12 EP EP06849951A patent/EP1984344B1/en active Active
- 2006-12-12 DK DK06849951.6T patent/DK1984344T3/da active
- 2006-12-12 ES ES06849951T patent/ES2395392T3/es active Active
- 2006-12-12 UA UAA200809740A patent/UA96936C2/uk unknown
- 2006-12-12 JP JP2008548561A patent/JP5483883B2/ja active Active
- 2006-12-12 PL PL06849951T patent/PL1984344T3/pl unknown
- 2006-12-12 CN CN201310082551.2A patent/CN103265495B/zh active Active
- 2006-12-12 EP EP11005146.3A patent/EP2386547B1/en active Active
- 2006-12-12 CN CN2006800499070A patent/CN101351451B/zh active Active
- 2006-12-12 ES ES11005146.3T patent/ES2684821T3/es active Active
- 2006-12-12 PT PT68499516T patent/PT1984344E/pt unknown
- 2006-12-12 NZ NZ568946A patent/NZ568946A/en unknown
- 2006-12-12 AU AU2006337137A patent/AU2006337137B2/en active Active
-
2008
- 2008-06-05 IL IL191998A patent/IL191998A/en active IP Right Grant
- 2008-06-30 EC EC2008008590A patent/ECSP088590A/es unknown
- 2008-07-28 NO NO20083324A patent/NO344848B1/no unknown
-
2009
- 2009-03-11 HK HK09102308.4A patent/HK1124841A1/xx unknown
-
2010
- 2010-03-30 US US12/750,278 patent/US8063057B2/en active Active
-
2011
- 2011-11-07 US US13/290,261 patent/US8629156B2/en active Active
Non-Patent Citations (1)
Title |
---|
None |
Cited By (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1848435A4 (en) * | 2005-01-25 | 2010-09-29 | Synta Pharmaceuticals Corp | COMPOUNDS FOR USE IN INFLAMMATION AND IMMUNE DISORDERS |
US8518950B2 (en) | 2005-01-25 | 2013-08-27 | Synta Pharmaceuticals Corp. | 2-amido pyrazines for inflammation and immune related uses |
EP1848435A2 (en) * | 2005-01-25 | 2007-10-31 | Synta Pharmaceuticals Corporation | Compounds for inflammation and immune-related uses |
US9090570B2 (en) | 2005-01-25 | 2015-07-28 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
US9493427B2 (en) | 2005-01-25 | 2016-11-15 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
JP2015164925A (ja) * | 2006-11-15 | 2015-09-17 | ワイエム・バイオサイエンスィーズ・オーストラリア・ピーティーワイ・リミテッドYM Biosciences Australia Pty Ltd | キナーゼ活性の阻害剤 |
EP3808740A1 (en) * | 2006-12-12 | 2021-04-21 | TerSera Therapeutics LLC | Oral dosage forms comprising 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
EA018150B1 (ru) * | 2006-12-12 | 2013-05-30 | Лексикон Фармасьютикалз, Инк. | Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения |
AU2007333120B2 (en) * | 2006-12-12 | 2013-02-07 | Tersera Therapeutics Llc | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
WO2008073933A3 (en) * | 2006-12-12 | 2008-11-06 | Lexicon Pharmaceuticals Inc | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
JP2010512416A (ja) * | 2006-12-12 | 2010-04-22 | レクシコン ファーマシューティカルズ インコーポレイテッド | 4−フェニル−6−(2,2,2−トリフルオロ−1−フェニルエトキシ)ピリミジン系化合物及びその使用方法 |
NO345062B1 (no) * | 2006-12-12 | 2020-09-14 | Lexicon Pharmaceuticals Inc | 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy) pyrimidinbaserte forbindelser og anvendelse derav |
EP2589600A1 (en) * | 2006-12-12 | 2013-05-08 | Lexicon Pharmaceuticals, Inc. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
TWI412365B (zh) * | 2006-12-12 | 2013-10-21 | Lexicon Pharmaceuticals Inc | 4-苯基-6-(2,2,2-三氟-1-苯乙氧基)嘧啶系化合物與其使用方法 |
EP3176159A1 (en) * | 2006-12-12 | 2017-06-07 | Lexicon Pharmaceuticals, Inc. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
WO2008073933A2 (en) | 2006-12-12 | 2008-06-19 | Lexicon Pharmaceuticals, Inc. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
WO2009002970A1 (en) * | 2007-06-26 | 2008-12-31 | Lexicon Pharmaceuticals, Inc. | Compositions comprising tryptophan hydroxylase inhibitors |
WO2009002964A1 (en) * | 2007-06-26 | 2008-12-31 | Lexicon Pharmaceuticals, Inc. | Methods of treating serotonin-mediated diseases and disorders |
US8093291B2 (en) * | 2007-06-26 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | Methods of using and compositions comprising tryptophan hydroxylase inhibitors |
WO2009014972A1 (en) * | 2007-07-26 | 2009-01-29 | Lexicon Pharmaceuticals, Inc. | Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein |
WO2009029499A1 (en) * | 2007-08-24 | 2009-03-05 | Lexicon Pharmaceuticals, Inc. | Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
JP2010536879A (ja) * | 2007-08-24 | 2010-12-02 | レクシコン ファーマシューティカルズ インコーポレイテッド | 4−フェニル−6−(2,2,2−トリフルオロ−1−フェニルエトキシ)ピリミジン系化合物を調製する方法 |
KR101582697B1 (ko) * | 2007-08-24 | 2016-01-05 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 4-페닐-6-(2,2,2-트리플루오로-1-페닐에톡시)피리미딘-기재화합물의 제조 방법 |
EP2529740A1 (en) * | 2007-08-24 | 2012-12-05 | Lexicon Pharmaceuticals, Inc. | Methods of preparing 4-Phenyl-6(2,2,2-Trifluoro-1-Phenylethoxy) Pyrimidine-based compounds. |
EP3318260A1 (en) * | 2007-08-24 | 2018-05-09 | Lexicon Pharmaceuticals, Inc. | Methods of preparing 4-phenyl-6-(2,2,2- trifluoro-1-phenylethoxy) pyrimidine-based compounds |
KR20100046026A (ko) * | 2007-08-24 | 2010-05-04 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 4-페닐-6-(2,2,2-트리플루오로-1-페닐에톡시)피리미딘-기재화합물의 제조 방법 |
CN101801384B (zh) * | 2007-08-24 | 2012-03-21 | 莱西肯医药有限公司 | 制备基于4-苯基-6-(2,2,2-三氟-1-苯基乙氧基)嘧啶的化合物的方法 |
RU2493156C2 (ru) * | 2007-08-24 | 2013-09-20 | Лексикон Фармасьютикалз, Инк. | Способы получения соединений на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина |
AU2008293679B2 (en) * | 2007-08-24 | 2013-09-12 | Tersera Therapeutics Llc | Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
KR101644657B1 (ko) * | 2007-09-28 | 2016-08-01 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 고체 형태의 (s)-에틸 2-아미노-3-(4-(2-아미노-6-((r)-1-(4-클로로-2-(3-메틸-1h-피라졸-1-일)페닐)-2,2,2-트리플루오로에톡시)-피리미딘-4-일)페닐)프로파노에이트 |
EA017275B1 (ru) * | 2007-09-28 | 2012-11-30 | Лексикон Фармасьютикалз, Инк. | Твердые формы (s)-этил-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1h-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата и способы их применения |
WO2009042733A1 (en) * | 2007-09-28 | 2009-04-02 | Lexicon Pharmaceuticals, Inc. | Solids forms of ( s) -ethyl 2-amin0-3- (4- (2 -amino- 6- ( (r) -1- (4-chl0r0-2- o-methyl-ih-pyrazol- 1-yl) phenyl) -2, 2, 2-trifluorethoxy) -pyrimidin-4-yl) phenyl) propanoate |
JP2010540551A (ja) * | 2007-09-28 | 2010-12-24 | レクシコン ファーマシューティカルズ インコーポレイテッド | (s)−エチル2−アミノ−3−(4−(2−アミノ−6−((r)−1−(4−クロロ−2−(3−メチル−1h−ピラゾール−1−イル)フェニル)−2,2,2−トリフルオロエトキシ)−ピリミジン−4−イル)フェニル)プロパノエートの固体形態 |
CN101809018A (zh) * | 2007-09-28 | 2010-08-18 | 莱西肯医药有限公司 | (s)-2-氨基-3-(4-(2-氨基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧基)-嘧啶-4-基)苯基)丙酸乙酯的固体形式及其使用方法 |
KR20100063736A (ko) * | 2007-09-28 | 2010-06-11 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 고체 형태의 (s)-에틸 2-아미노-3-(4-(2-아미노-6-((r)-1-(4-클로로-2-(3-메틸-1h-피라졸-1-일)페닐)-2,2,2-트리플루오로에톡시)-피리미딘-4-일)페닐)프로파노에이트 |
AU2008304439B2 (en) * | 2007-09-28 | 2013-10-17 | Tersera Therapeutics Llc | (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluorethoxy)pyrimidin-4-yl)phenyl)propanoate |
WO2009048864A1 (en) * | 2007-10-08 | 2009-04-16 | Lexicon Pharmaceuticals, Inc. | Solid forms of (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
JP2014028828A (ja) * | 2008-02-04 | 2014-02-13 | Mercury Therapeutics Inc | Ampk調節因子 |
JP2011511008A (ja) * | 2008-02-04 | 2011-04-07 | マーキュリー セラピューティクス,インコーポレイテッド | Ampk調節因子 |
US8980895B2 (en) | 2008-02-04 | 2015-03-17 | Mercury Therapeutics, Inc. | AMPK modulators |
JP2011516486A (ja) * | 2008-03-31 | 2011-05-26 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 骨質量疾患の診断、予防、及び治療方法 |
EP2282756A4 (en) * | 2008-03-31 | 2012-05-02 | Univ Columbia | METHOD FOR DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF BONE MEASURES |
US8759364B2 (en) | 2008-03-31 | 2014-06-24 | The Trustees Of Columbia University In The City Of New York | Methods of treating bone mass diseases |
EP2282756A1 (en) * | 2008-03-31 | 2011-02-16 | The Trustees of Columbia University in the City of New York | Methods of diagnosing, preventing and treating bone mass diseases |
WO2010039957A1 (en) * | 2008-10-03 | 2010-04-08 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors and methods of their use |
WO2010047712A1 (en) * | 2008-10-24 | 2010-04-29 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
CN102203069A (zh) * | 2008-10-24 | 2011-09-28 | 莱西肯医药有限公司 | 被取代的苯基丙氨酸的制备方法 |
WO2010062829A1 (en) * | 2008-11-28 | 2010-06-03 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for treating osteoporosis |
WO2010065333A1 (en) * | 2008-12-01 | 2010-06-10 | Lexicon Pharmaceuticals, Inc. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis |
US8815883B2 (en) | 2009-11-02 | 2014-08-26 | The Trustees Of Columbia Unviersity In The City Of New York | Compounds and methods for inhibiting serotonin synthesis |
US20130053343A1 (en) * | 2009-11-02 | 2013-02-28 | The Trustees of Columbia University in th City of | Compounds and methods for inhibiting serotonin synthesis |
WO2011056916A1 (en) * | 2009-11-05 | 2011-05-12 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of cancer |
US10894787B2 (en) | 2010-09-22 | 2021-01-19 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
WO2013131872A1 (en) * | 2012-03-05 | 2013-09-12 | Ge Healthcare Limited | Imaging neural activity |
WO2014195847A2 (en) | 2013-06-03 | 2014-12-11 | Actelion Pharmaceuticals Ltd | Novel use of stable isotope labeled l-tryptophan |
US9750740B2 (en) | 2013-09-06 | 2017-09-05 | Kanos Pharmaceuticals, Inc. | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
US9199994B2 (en) | 2013-09-06 | 2015-12-01 | Karos Pharmaceuticals, Inc. | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
US9512122B2 (en) | 2013-09-06 | 2016-12-06 | Karos Pharmaceuticals, Inc. | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
US11759462B2 (en) | 2013-09-06 | 2023-09-19 | Altavant Sciences Gmbh | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
US10946018B2 (en) | 2013-09-06 | 2021-03-16 | Roivant Sciences Gmbh | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
US10660893B2 (en) | 2013-09-06 | 2020-05-26 | ROIVANT SCIENCES, GmbH | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
US10350208B2 (en) | 2013-09-06 | 2019-07-16 | Roivant Sciences Gmbh | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
US10045988B2 (en) | 2013-09-06 | 2018-08-14 | Roivant Sciences Gmbh | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
WO2015075025A1 (en) | 2013-11-19 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase |
WO2015075023A1 (en) | 2013-11-19 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
KR102390234B1 (ko) | 2013-11-19 | 2022-04-22 | 액테리온 파마슈티칼 리미티드 | 트리시클릭 피페리딘 화합물 |
EA029391B1 (ru) * | 2013-11-19 | 2018-03-30 | Актелион Фармасьютиклз Лтд | Трициклические соединения пиперидина |
AU2014352008B2 (en) * | 2013-11-19 | 2018-08-16 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
US10189839B2 (en) | 2013-11-19 | 2019-01-29 | Actelion Pharmaceuticals Ltd | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase |
TWI658043B (zh) * | 2013-11-19 | 2019-05-01 | 艾克泰聯製藥有限公司 | 三環哌啶化合物 |
US9765092B2 (en) | 2013-11-19 | 2017-09-19 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
KR20160077216A (ko) * | 2013-11-19 | 2016-07-01 | 액테리온 파마슈티칼 리미티드 | 트리시클릭 피페리딘 화합물 |
CN105745214A (zh) * | 2013-11-19 | 2016-07-06 | 埃科特莱茵药品有限公司 | 三环哌啶化合物 |
WO2015089137A1 (en) * | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
US9783522B2 (en) | 2014-04-24 | 2017-10-10 | Mitsubishi Tanabe Pharma Corporation | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof |
US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
US10710948B2 (en) | 2015-03-05 | 2020-07-14 | Roivant Sciences Gmbh | Processes for preparing (R)-1-(5-chloro-[1,1″-biphenyl] -2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1″-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
WO2016177690A1 (en) | 2015-05-04 | 2016-11-10 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
CN107567449A (zh) * | 2015-05-04 | 2018-01-09 | 埃科特莱茵药品有限公司 | 三环哌啶化合物 |
US11884626B2 (en) | 2015-06-22 | 2024-01-30 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1984344B1 (en) | Multicyclic amino acid derivatives and methods of their use | |
AU2008275179B2 (en) | Methods and compositions for treating pulmonary hypertension and related diseases and disorders | |
CA2691003A1 (en) | Methods of treating serotonin-mediated diseases and disorders | |
AU2008268409B2 (en) | Compositions comprising tryptophan hydroxylase inhibitors | |
EP2178536A1 (en) | Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein | |
WO2010062829A1 (en) | Tryptophan hydroxylase inhibitors for treating osteoporosis | |
MX2008008483A (en) | Multicyclic amino acid derivatives and methods of their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680049907.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006337137 Country of ref document: AU Ref document number: 568946 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501522 Country of ref document: PH Ref document number: 5368/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2635531 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2006337137 Country of ref document: AU Date of ref document: 20061212 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008548561 Country of ref document: JP Ref document number: 2008061101 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/008483 Country of ref document: MX Ref document number: 1020087015697 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08074441 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200870127 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006849951 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06849951 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: PI0620756 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080627 |